EIPICO Achieves a Double Milestone  EIPICO announced a significant dual achievement regarding Obtains (EDA License for EIPICO 3 Factory) and the launch of its new biosimilar product (ADALIMAB), The event was chaired by both of
Prof. Dr. Samir El-Badawi, Professor of Rheumatology at Cairo University and President of the Egyptian Society for Osteoporosis and Geriatrics.
Dr. Ahmed Kelani, Chairman and Managing Director of EIPICO, announced that the EIPICO 3 factory has obtained the necessary licenses from the Egyptian Drug Authority as well as the license from and the Industrial Development Authority, paving the way for the start of its operational phase in the first quarter of 2026.
This marks a new era for EIPICO in the pharmaceutical industry in Egypt, as the factory is the first in Egypt to produce Biosimilar & Biologicals from cell culture up to finished product, with investment of 100 $ million
ADALIMAB has been awarded to be supplied to the Unified Procurement Agency UPA, to ensure its availability to a large segment of patients. Additionally, moreover EIPICO received a request to export ADALIMAB to Namibia, in of the confidence in the quality of EIPICO's products, which are exported to over 60 countries, with $ 60 million, accounting for 25% of Egypt's total pharmaceutical exports
Dr. Kelani emphasized that this achievement is a response to the government's vision to localize and deepen the pharmaceutical industry in Egypt, reducing the country's reliance on imported medicines and raw materials. EIPICO aims to provide young Egyptians with the skills to handle global advanced technology and produce biological medicines,
The conference was attended by prominent rheumatologists from various medical sectors in Egypt, who praised EIPICO's efforts to pro
They valued EIPICO efforts as a leading national company in producing ADALIMAB for the first time in Egypt and making it accessible to the citizens.
They also emphasized that the Scientific studies have confirmed ADALIMAB therapeutic efficacy and quality are equivalent to those of the imported counterpart.
The conference also featured contributions from:Professor Dr. Amal El-Ganzouri, Professor of Rheumatology and Rehabilitation at Ain Shams University,Prof. Dr. Hani Nagi Ahmed, Consultant of Rheumatology and Immunology, Director of the Rheumatology and Rehabilitation Center in Agouza for the Armed Forces, and Head of the Conservative Treatment UnitCons. Dr. Medhat Mohy El-Din Abdel Latif, Consultant of Physical Medicine and Rheumatology, and Head of the Rheumatology and Immunology Committees at the General Authority for Health InsuranceProf. Dr. Mohamed Mahmoud El-Waked, Professor of Rheumatology and Clinical Immunology at Cairo UniversityDr. Assem Al-Aqbawi, Head of the Commercial Sector at EIPICO PharmaceuticalsDr. Hesham EL Tawdy, Marketing Manager EIPICO 3 – Biological & Biosimilar
|